169 related articles for article (PubMed ID: 29066476)
21. RET proto oncogene mutation detection and medullary thyroid carcinoma prevention.
Yeganeh MZ; Sheikholeslami S; Hedayati M
Asian Pac J Cancer Prev; 2015; 16(6):2107-17. PubMed ID: 25824727
[TBL] [Abstract][Full Text] [Related]
22. Sporadic minute medullary thyroid carcinoma with a double RET mutation: A case report.
Yamamoto H; Ishii J; Chiba T; Nakazato Y; Hirano K; Kamma H
Pathol Int; 2017 Nov; 67(11):580-584. PubMed ID: 28952196
[TBL] [Abstract][Full Text] [Related]
23. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
24. Deletions of CDKN2C in multiple myeloma: biological and clinical implications.
Leone PE; Walker BA; Jenner MW; Chiecchio L; Dagrada G; Protheroe RK; Johnson DC; Dickens NJ; Brito JL; Else M; Gonzalez D; Ross FM; Chen-Kiang S; Davies FE; Morgan GJ
Clin Cancer Res; 2008 Oct; 14(19):6033-41. PubMed ID: 18829482
[TBL] [Abstract][Full Text] [Related]
25. Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas.
Costa-Guda J; Soong CP; Parekh VI; Agarwal SK; Arnold A
Horm Cancer; 2013 Oct; 4(5):301-7. PubMed ID: 23715670
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
27. Novel point mutations and allele loss at the RET locus in sporadic medullary thyroid carcinomas.
Uchino S; Noguchi S; Adachi M; Sato M; Yamashita H; Watanabe S; Murakami T; Toda M; Murakami N; Yamashita H
Jpn J Cancer Res; 1998 Apr; 89(4):411-8. PubMed ID: 9617347
[TBL] [Abstract][Full Text] [Related]
28. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma.
Marsh DJ; Theodosopoulos G; Martin-Schulte K; Richardson AL; Philips J; Röher HD; Delbridge L; Robinson BG
J Clin Endocrinol Metab; 2003 Apr; 88(4):1866-72. PubMed ID: 12679485
[TBL] [Abstract][Full Text] [Related]
30. Tumour suppressor gene (CDKNA2) status on chromosome 9p in resected renal tissue improves prognosis of localised kidney cancer.
El-Mokadem I; Kidd T; Pratt N; Fleming S; Nabi G
Oncotarget; 2016 Nov; 7(45):73045-73054. PubMed ID: 27682877
[TBL] [Abstract][Full Text] [Related]
31. RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM; Cavaco BM; Leite V
Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
[TBL] [Abstract][Full Text] [Related]
32. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
33. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.
Rodríguez-Antona C; Pallares J; Montero-Conde C; Inglada-Pérez L; Castelblanco E; Landa I; Leskelä S; Leandro-García LJ; López-Jiménez E; Letón R; Cascón A; Lerma E; Martin MC; Carralero MC; Mauricio D; Cigudosa JC; Matias-Guiu X; Robledo M
Endocr Relat Cancer; 2010 Mar; 17(1):7-16. PubMed ID: 19776290
[TBL] [Abstract][Full Text] [Related]
34. Thyroid C-Cell Biology and Oncogenic Transformation.
Cote GJ; Grubbs EG; Hofmann MC
Recent Results Cancer Res; 2015; 204():1-39. PubMed ID: 26494382
[TBL] [Abstract][Full Text] [Related]
35. Two GEO MicroRNA Expression Profile Based High-Throughput Screen to Identify MicroRNA-31-3p Regulating Growth of Medullary Thyroid Carcinoma Cell by Targeting RASA2.
Jiang M; Shi X; Zhu H; Wei W; Li J
Med Sci Monit; 2019 Jul; 25():5170-5180. PubMed ID: 31298226
[TBL] [Abstract][Full Text] [Related]
36. [
Wang Y; Du LL; Hou SH; Han CZ; Zhao XW; Wang WG; Xu XQ; Jing JX
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):873-876. PubMed ID: 27938622
[TBL] [Abstract][Full Text] [Related]
37. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
[TBL] [Abstract][Full Text] [Related]
38. High-resolution analysis of alterations in medullary thyroid carcinoma genomes.
Flicker K; Ulz P; Höger H; Zeitlhofer P; Haas OA; Behmel A; Buchinger W; Scheuba C; Niederle B; Pfragner R; Speicher MR
Int J Cancer; 2012 Jul; 131(2):E66-73. PubMed ID: 22038905
[TBL] [Abstract][Full Text] [Related]
39. mTOR activation in medullary thyroid carcinoma with RAS mutation.
Lyra J; Vinagre J; Batista R; Pinto V; Prazeres H; Rodrigues F; Eloy C; Sobrinho-Simões M; Soares P
Eur J Endocrinol; 2014 Nov; 171(5):633-40. PubMed ID: 25163725
[TBL] [Abstract][Full Text] [Related]
40. Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease.
Jayakody S; Reagh J; Bullock M; Aniss A; Clifton-Bligh R; Learoyd D; Robinson B; Delbridge L; Sidhu S; Gill AJ; Sywak M
World J Surg; 2018 May; 42(5):1432-1439. PubMed ID: 29484475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
